India's bioeconomy has expanded nearly 20-fold in a decade. Critically analyse the drivers and the equity concerns.

Q. India's bioeconomy has expanded nearly 20-fold in a decade. Critically analyse the drivers and the equity concerns. (15 marks, 250-350 words)

India's bioeconomy — economic activity from biological resources and biotechnology — has grown from about $10 billion in 2014 to roughly $190 billion in 2026, with a target of $300 billion by 2030 [1][4]. The expansion is real and policy-driven, but its benefits remain unevenly distributed across regions, firms and social groups.

Drivers of the expansion - Policy architecture: the BioE3 Policy, approved by the Cabinet on 24 August 2024, anchors high-performance biomanufacturing through Bio-AI Hubs, Biofoundries and Biomanufacturing Hubs [2]. - Startup ecosystem: biotech startups rose from about 50 in 2014 to several thousand today, incubated largely through BIRAC under the Department of Biotechnology [1][4]. - Crisis-tested capability: indigenous Covid-19 vaccine development demonstrated end-to-end capacity from R&D to mass manufacturing [1]. - Convergence and demand pull: AI-enabled biology, precision biotherapeutics, smart proteins and climate-resilient agriculture opened high-value segments [2]. - Institutional analogue: the parallel space reform — a single-window IN-SPACe and nearly 400 startups against one in 2014 — shows how regulatory liberalisation multiplies private entry [3].

Equity concerns - Spatial concentration: activity clusters in a few biotech corridors and metros; the DBT–State partnerships under BioE3 are a corrective still at an early stage [2]. - Sectoral skew: growth is dominated by biopharma and bio-industrial segments, while bio-agriculture — where most livelihoods lie — contributes a smaller share [4]. - Access versus profit: precision biotherapeutics risk high pricing, straining affordable access consistent with Article 21's right to health. - Benefit-sharing: commercial use of biological resources and traditional knowledge raises questions of fair returns to local communities under the biodiversity framework. - Skill divide: value capture favours a small research-intensive workforce, limiting the "Employment" pillar's reach.

The 20-fold rise reflects genuine capability-building rather than statistical accident, yet scale alone is not development. Realising the $300 billion goal equitably requires decentralised biofoundries in lagging states, stronger bio-agriculture linkages for farmers, and transparent benefit-sharing — aligning BioE3's employment and environment pillars with SDG-10's promise of reduced inequality.

(~330 words)

Sources: 1. $10 Billion to 190 Billion Bioeconomy: India's Science Story touches New Heights in 12 Years (PIB, June 2026) — bioeconomy growth from $10 bn to $190 bn; startup and vaccine ecosystem 2. Cabinet approves BioE3 Policy for Fostering High Performance Biomanufacturing (PIB, 24 Aug 2024) — BioE3 pillars, thematic sectors, state partnerships 3. India's space economy at $8.4 billion, nearly 400 start-ups active after sector opened to private players (PIB) — IN-SPACe single-window reform and startup growth 4. India's Bioeconomy to Touch $300 Billion by 2030, Says Dr. Jitendra Singh (PIB) — $300 bn target, sectoral composition, startup numbers